+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Type 2 Diabetes Mellitus Treatment Market - Global Forecast to 2030- Product Image
Type 2 Diabetes Mellitus Treatment Market - Global Forecast to 2030- Product Image
New

Type 2 Diabetes Mellitus Treatment Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6079010
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Type 2 diabetes persists as one of the most pervasive chronic diseases worldwide, imposing substantial clinical, economic, and societal burdens. Advances in pharmacology, digital health, and care delivery models have reshaped treatment paradigms, delivering improved glycemic control and patient adherence. Amid evolving regulatory frameworks and shifting payer expectations, stakeholders across the continuum are reevaluating therapeutic strategies to optimize outcomes while containing costs. This executive summary offers a concise yet comprehensive overview of the forces redefining the Type 2 diabetes treatment landscape, setting the stage for an in-depth analysis of transformative trends, policy impacts, and actionable insights for industry leaders.

Transformative Shifts in the Type 2 Diabetes Landscape

Over the past decade, the Type 2 diabetes arena has experienced several paradigm shifts. First, the emergence of glucagon-like peptide-1 receptor agonists established a new standard for weight loss and cardiovascular risk reduction, prompting a reevaluation of traditional insulin-centric regimens. Simultaneously, the proliferation of continuous glucose monitoring systems and smart insulin pens has enabled real-time data sharing between patients and providers, driving more personalized titration protocols.

Value-based contracting has gained traction among payers, incentivizing outcomes over volume and accelerating adoption of therapies demonstrating demonstrable reductions in hospitalizations and complications. Digital therapeutics platforms now complement pharmacotherapy with behavior-modification modules, fostering self-management and remote monitoring. Moreover, regulatory agencies have streamlined approval pathways for biosimilars and novel combination products, accelerating market entry and fostering competition. These converging forces are rewriting the rules of engagement, challenging incumbents to innovate or risk obsolescence while presenting new entrants with fertile ground for disruptive growth.

Cumulative Impact of United States Tariffs Effective 2025

In early 2025, new tariffs on imported active pharmaceutical ingredients and finished formulations introduced an additional layer of complexity to the supply chain. These duties, applied uniformly across branded and generic products, have led to modest yet meaningful cost pressures, compelling manufacturers and distributors to reassess procurement strategies. Many have sought to diversify sourcing, forging partnerships with domestic and near-shoring suppliers to mitigate exposure to fluctuating duties.

Meanwhile, wholesalers and pharmacy benefit managers have renegotiated rebate structures and distribution fees to offset margin erosion, with some redirecting volume toward therapies manufactured in tariff-exempt jurisdictions. Hospitals and clinics, facing higher acquisition costs, are increasingly prioritizing therapies with proven long-term cost savings through reduced complication rates. Collectively, these adaptations underscore the sector’s agility in preserving patient access and maintaining competitive pricing despite the headwinds of newly imposed trade barriers.

Key Segmentation Insights Shaping Clinical and Commercial Strategies

A nuanced understanding of patient and provider heterogeneity is essential for targeted intervention. When dissecting treatment modalities, the market divides into injectable therapies-comprised of GLP-1 receptor agonists and traditional insulin regimens-and oral medications, which span first-line biguanides, DPP-4 inhibitors, and sulfonylureas. Patient demographics reveal distinct adherence patterns and risk profiles: adults aged 40 to 59 often prioritize therapies with minimal lifestyle disruption, whereas those 60 and above may favor convenience and dosing simplicity. Younger cohorts, from adolescents to children with early-onset disease, require pediatric-friendly formulations and robust educational support.

On the delivery side, primary care settings continue to serve as the cornerstone for initial diagnosis and long-term management, but rising patient volumes have driven referrals to specialty diabetes centers, where multidisciplinary teams can optimize complex regimens. Retail pharmacies are also expanding point-of-care testing services, elevating the pharmacist’s role in medication titration and patient counseling. Finally, advances in monitoring devices-from continuous glucose sensors to wearable insulin pumps and pens-are intersecting, creating an ecosystem in which data interoperability and patient engagement tools are as critical as the therapies themselves.

Key Regional Insights Informing Market Access and Distribution

Regional dynamics are shaping adoption curves and investment priorities. In the Americas, established reimbursement frameworks and high consumer awareness have expedited uptake of next-generation injectables and digital health solutions. Payors in North America increasingly link reimbursement to performance metrics, reinforcing value propositions tied to reduced hospital admissions. Across Latin America, emerging healthcare infrastructures and heterogeneous regulatory environments call for adaptable distribution models and tiered pricing approaches.

In Europe, the Middle East, and Africa, reimbursement variability and public health imperatives drive divergent access levels. Western European markets emphasize health-technology assessments to validate long-term cost-effectiveness, while Middle Eastern countries are investing in national diabetes programs that encourage public-private partnerships. African markets, still grappling with resource constraints, show promise through telemedicine initiatives and community health worker training to extend reach. Meanwhile, Asia-Pacific presents a mosaic of opportunity: mature markets like Japan and Australia adopt innovative therapies rapidly, whereas Southeast Asian and South Asian countries focus on scaling basic oral regimens and expanding primary care capacity.

Key Competitive Insights from Leading Pharmaceutical Innovators

Leadership in this evolving environment depends on robust portfolios and forward-looking innovation pipelines. AstraZeneca plc has distinguished itself by integrating cardiovascular outcome data into its GLP-1 receptor agonist program, reinforcing its value proposition. Boehringer Ingelheim GmbH leverages strategic alliances to expand its oral DPP-4 inhibitor offerings and explore fixed-dose combinations. Eli Lilly and Company continues to broaden its insulin business with novel basal and ultra-rapid analogs, while also investing heavily in connected devices.

Merck & Co., Inc. has prioritized research into adjunctive therapies that address comorbidities, such as nonalcoholic steatohepatitis, to create differentiated treatment regimens. Novo Nordisk A/S remains at the forefront of weight-focused diabetes care, coupling dynamic pricing models with patient support programs to maximize access. Sanofi S.A. has recalibrated its commercial strategy to emphasize specialty centers and digital coaching platforms, enhancing adherence and reinforcing its broad insulin franchise. Together, these organizations exemplify diverse approaches to driving growth, from incremental innovation to disruptive partnerships.

Actionable Recommendations for Industry Leaders

To thrive amid intensified competition and policy shifts, industry leaders should consider the following actions:
  1. Strengthen Value Demonstrations: Collaborate with payers to design real-world evidence studies that quantify reductions in complications, hospitalizations, and total cost of care. Prioritize data sharing and transparent outcomes reporting.
  2. Expand Integrated Care Solutions: Partner with digital health providers, device manufacturers, and specialty clinics to deliver end-to-end disease management platforms that combine pharmacotherapy with remote monitoring, teleconsultations, and behavioral coaching.
  3. Diversify Supply Chains: Mitigate tariff exposure by developing dual sourcing strategies, near-shoring agreements, and investments in local manufacturing capabilities, ensuring continuity and cost stability.
  4. Personalize Access Models: Deploy tiered pricing and patient assistance programs calibrated to regional economic conditions and demographic segments, from pediatric onset to geriatric populations.
  5. Foster Cross-Sector Alliances: Engage with technology firms, payers, and patient advocacy groups to co-create novel reimbursement structures, such as outcomes-based contracts and subscription models, that align incentives across stakeholders.

Conclusion and Strategic Outlook

The Type 2 diabetes treatment ecosystem stands at a pivotal juncture, propelled by scientific breakthroughs, digital integration, and evolving policy landscapes. Stakeholders who embrace data-driven decision-making, fortify supply resilience, and refine value propositions will secure competitive advantage and improve patient outcomes. By leveraging segmentation insights across modalities, demographics, providers, and technologies, companies can tailor offerings that resonate with diverse patient needs and regional demands. Collaboration-both within the healthcare sector and across adjacent industries-will accelerate innovation and unlock sustainable growth pathways. Ultimately, the capacity to adapt swiftly and execute on clear, evidence-based strategies will define success in this dynamic market.

Market Segmentation & Coverage

This research report categorizes the Type 2 Diabetes Mellitus Treatment Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Injectable Therapies
    • GLP-1 Receptor Agonists
    • Insulin Therapies
  • Oral Medications
    • Biguanides
    • DPP-4 Inhibitors
    • Sulfonylureas
  • Adult Population
    • Aged 40-59
    • Aged 60 and Above
  • Youth Population
    • Adolescents Aged 10-19
    • Children Diagnosed with Diabetes
  • Hospitals
    • Primary Care Facilities
    • Specialty Diabetes Centers
  • Independent Clinics
  • Retail Pharmacies
  • Continuous Glucose Monitoring Systems
  • Insulin Delivery Devices
    • External Insulin Pumps
    • Insulin Pens

This research report categorizes the Type 2 Diabetes Mellitus Treatment Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Type 2 Diabetes Mellitus Treatment Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Sanofi S.A.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Type 2 Diabetes Mellitus Treatment Market, by Treatment Modalities
8.1. Introduction
8.2. Injectable Therapies
8.2.1. GLP-1 Receptor Agonists
8.2.2. Insulin Therapies
8.3. Oral Medications
8.3.1. Biguanides
8.3.2. DPP-4 Inhibitors
8.3.3. Sulfonylureas
9. Type 2 Diabetes Mellitus Treatment Market, by Patient Demographics
9.1. Introduction
9.2. Adult Population
9.2.1. Aged 40-59
9.2.2. Aged 60 and Above
9.3. Youth Population
9.3.1. Adolescents Aged 10-19
9.3.2. Children Diagnosed with Diabetes
10. Type 2 Diabetes Mellitus Treatment Market, by Treatment Providers
10.1. Introduction
10.2. Hospitals
10.2.1. Primary Care Facilities
10.2.2. Specialty Diabetes Centers
10.3. Independent Clinics
10.4. Retail Pharmacies
11. Type 2 Diabetes Mellitus Treatment Market, by Technology and Devices
11.1. Introduction
11.2. Continuous Glucose Monitoring Systems
11.3. Insulin Delivery Devices
11.3.1. External Insulin Pumps
11.3.2. Insulin Pens
12. Americas Type 2 Diabetes Mellitus Treatment Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Type 2 Diabetes Mellitus Treatment Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Type 2 Diabetes Mellitus Treatment Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AstraZeneca plc
15.3.2. Boehringer Ingelheim GmbH
15.3.3. Eli Lilly and Company
15.3.4. Merck & Co., Inc.
15.3.5. Novo Nordisk A/S
15.3.6. Sanofi S.A.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. TYPE 2 DIABETES MELLITUS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. TYPE 2 DIABETES MELLITUS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. TYPE 2 DIABETES MELLITUS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. TYPE 2 DIABETES MELLITUS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. TYPE 2 DIABETES MELLITUS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TYPE 2 DIABETES MELLITUS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY AGED 40-59, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY AGED 60 AND ABOVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADOLESCENTS AGED 10-19, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY CHILDREN DIAGNOSED WITH DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PRIMARY CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY SPECIALTY DIABETES CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY EXTERNAL INSULIN PUMPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN PENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 69. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 70. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 71. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 72. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 73. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 74. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 75. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 76. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 77. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 78. CANADA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 79. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 80. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 81. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 83. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 84. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 85. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 87. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 88. MEXICO TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 114. AUSTRALIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 115. AUSTRALIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 116. AUSTRALIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 119. AUSTRALIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 121. CHINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 122. CHINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 123. CHINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 124. CHINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 125. CHINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 126. CHINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 127. CHINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 128. CHINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 129. CHINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 130. CHINA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 131. INDIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 132. INDIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 133. INDIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 134. INDIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 135. INDIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 136. INDIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 137. INDIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 138. INDIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 139. INDIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 140. INDIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 141. INDONESIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 142. INDONESIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 143. INDONESIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 144. INDONESIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 145. INDONESIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 146. INDONESIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 147. INDONESIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 148. INDONESIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 149. INDONESIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 150. INDONESIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 151. JAPAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 152. JAPAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 153. JAPAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 154. JAPAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 155. JAPAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 156. JAPAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 157. JAPAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 158. JAPAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 159. JAPAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 160. JAPAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 161. MALAYSIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 162. MALAYSIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 163. MALAYSIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 164. MALAYSIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 165. MALAYSIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 166. MALAYSIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 167. MALAYSIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 168. MALAYSIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 169. MALAYSIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 170. MALAYSIA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 171. PHILIPPINES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 172. PHILIPPINES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 173. PHILIPPINES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 174. PHILIPPINES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 175. PHILIPPINES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 176. PHILIPPINES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 177. PHILIPPINES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 178. PHILIPPINES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 179. PHILIPPINES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 180. PHILIPPINES TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 181. SINGAPORE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 182. SINGAPORE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 183. SINGAPORE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 184. SINGAPORE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 185. SINGAPORE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 186. SINGAPORE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 187. SINGAPORE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 188. SINGAPORE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 189. SINGAPORE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 190. SINGAPORE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 191. SOUTH KOREA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 192. SOUTH KOREA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 193. SOUTH KOREA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 194. SOUTH KOREA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 195. SOUTH KOREA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 196. SOUTH KOREA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 201. TAIWAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 202. TAIWAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 203. TAIWAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 204. TAIWAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 205. TAIWAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 206. TAIWAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 207. TAIWAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 208. TAIWAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 209. TAIWAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 210. TAIWAN TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 211. THAILAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 212. THAILAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 213. THAILAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 214. THAILAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 215. THAILAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 216. THAILAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 217. THAILAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 218. THAILAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 219. THAILAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 220. THAILAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 221. VIETNAM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 222. VIETNAM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 223. VIETNAM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 224. VIETNAM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 225. VIETNAM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 226. VIETNAM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 242. DENMARK TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 243. DENMARK TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 244. DENMARK TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 245. DENMARK TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 246. DENMARK TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 247. DENMARK TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 248. DENMARK TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 249. DENMARK TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 250. DENMARK TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 251. DENMARK TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 252. EGYPT TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 253. EGYPT TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 254. EGYPT TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 255. EGYPT TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 256. EGYPT TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 257. EGYPT TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 258. EGYPT TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 259. EGYPT TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 260. EGYPT TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 261. EGYPT TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 262. FINLAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 263. FINLAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 264. FINLAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 265. FINLAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 266. FINLAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 267. FINLAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 268. FINLAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 269. FINLAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 270. FINLAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 271. FINLAND TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 272. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 273. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 274. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 275. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 276. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ADULT POPULATION, 2018-2030 (USD MILLION)
TABLE 277. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY YOUTH POPULATION, 2018-2030 (USD MILLION)
TABLE 278. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT PROVIDERS, 2018-2030 (USD MILLION)
TABLE 279. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 280. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TECHNOLOGY AND DEVICES, 2018-2030 (USD MILLION)
TABLE 281. FRANCE TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INSULIN DELIVERY DEVICES, 2018-2030 (USD MILLION)
TABLE 282. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY TREATMENT MODALITIES, 2018-2030 (USD MILLION)
TABLE 283. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY INJECTABLE THERAPIES, 2018-2030 (USD MILLION)
TABLE 284. GERMANY TYPE 2 DIABETES MELLITUS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD

Companies Mentioned

  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Sanofi S.A.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Type 2 Diabetes Mellitus Treatment - Global Strategic Business Report - Product Image

Type 2 Diabetes Mellitus Treatment - Global Strategic Business Report

  • Report
  • 72 Pages
  • Global
From
Insulin Glargine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Insulin Glargine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 106 Pages
  • Global
From
Liraglutide and Semaglutide - Global Strategic Business Report - Product Image

Liraglutide and Semaglutide - Global Strategic Business Report

  • Report
  • 451 Pages
  • Global
From
Cardiovascular Outcomes of Treatments available for Patients with Type 1 and 2 Diabetes, An Issue of Endocrinology and Metabolism Clinics of North America. The Clinics: Internal Medicine Volume 47-1 - Product Image

Cardiovascular Outcomes of Treatments available for Patients with Type 1 and 2 Diabetes, An Issue of Endocrinology and Metabolism Clinics of North America. The Clinics: Internal Medicine Volume 47-1

  • Book
  • North America
Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025 - Product Image

Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.